|
A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury Clinical Trials Information presented on Clinical Trials Search is not designed to be a substitute for certified medical advice, trips or professional assistance with a real medical doctor. We aren't docs. Always confer with your doctor about A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury conditions. Clinical Trials Search.org is a website committed to listing clinical research studies in human subjects. A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury Clinical research trials and A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury health trials happen in many of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the effectualness of new does drugs. The intention of the studies / projects is to figure out particular human healthcare questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to detect cures for all forms of circumstances, like A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury. A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury Clinical Trials and other clinical trials allow for volunteers to undergo medical treatment options before they are available to the general public. Most times the subjects get treatment for free of charge, and occasionally they are paid for their time. Occasionally there is a cost for a A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury clinical trial. Subjects frequently get the best healthcare possible for their A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury condition. Hazards are a reality, however, and could include more or frequent mD visits, health risks (possibly life-jeopardizing), and/or the treatment being ineffectual. Trials are federally regulated with exacting guidelines to protect clinical trials patients.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury  A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury
A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury
For Condition: Acute Lung Injury,Respiratory Distress Syndrome, Adult
Status: No longer recruiting
Sponsor(s): Eli Lilly and Company ,
Synopsis: The purpose of this study is to determine whether sivelestat will reduce the amount of time a patient must spend on a ventilator and/or increase the chance of survival of patients with acute lung injury.
Details: Acute lung injury often develops as a result of severe infection, sepsis, severe injuries, inhalation of foreign substances into the lungs, or pneumonia. The tissues and blood vessels in the lungs become inflammed, and the body does not receive enough oxygen. Patients with this condition are placed on a ventilator to assist with breathing. Patients entered into this study will be randomly assigned to one of two treatment groups: a sivelestat group or a placebo group. Once entered into the study, patients are monitored for up to 6 months.
Eligibility:
Study Type: Interventional, Treatment, Randomized, Double-Blind, Placebo Control, Parallel Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: Inclusion Criteria - show evidence of acute lung injury - be on mechanical ventilation Exclusion Criteria - have undergone certain organ transplants - have severe underlying medical problems - be unlikely to survive - be pregnant or breast-feeding
Total Enrollment: 600
Location and Contact Information:
Additional Information:
Study ID Numbers: 6025;
Study Start Date: August 2001
Record last reviewed: September 2002
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00036062
Other Respiratory Distress Syndrome, Adult Studies:
1. Etanercept for Non-Infectious Lung Injury Following Bone Marrow Transplantation
2. Phase I Study of Vasoactive Intestinal Peptide in Patients with Acute Respiratory Distress Syndrome and Sepsis
3. A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury
Related Studies:
Other Respiratory Distress Syndrome, Adult Clinical Trials
Other Maine Clinical Trials
Other Portland Clinical Trials
A Phase II Study to Determine the Efficacy and Safety of Sivelestat in Subjects with Acute Lung Injury
|
|
|
|
|
|
|
|
